Foamix Pharmaceutical recently announced that its drug for treating moderate-to-severe acne has met the main goals of its third late-stage study. Foamix is a specialised pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
The drug showed a significant reduction in the number of inflammatory lesions in the trial, the company said. Foamix added the drug’s safety profile was also found to be consistent with its two prior late-stage studies.
Acne is a chronic, inflammatory skin condition that affects the skin’s oil glands and hair follicles. It is characterized by both inflammatory lesions (papules and pustules) and non-inflammatory lesions (open and closed comedones) affecting primarily the face and other areas of the body. Acne affects approximately 40 to 50 million people in the U.S. alone, of whom approximately 10 million have a moderate-to-severe disease that significantly impacts self-esteem and quality of life. For most people, acne diminishes over time and tends to disappear or decrease, by age 25. However, some individuals, particularly women, can experience acne much later in life.